How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?
Background Lp(a) (lipoprotein[a]) plays an important role in predicting cardiovascular events in patients with coronary artery disease through its proatherogenic and prothrombotic effects. We hypothesized that prolonged dual antiplatelet therapy (DAPT) might be beneficial for patients undergoing per...
Main Authors: | Kongyong Cui, Dong Yin, Chenggang Zhu, Weihua Song, Hongjian Wang, Lei Jia, Rui Zhang, Haoyu Wang, Zhongxing Cai, Lei Feng, Kefei Dou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-05-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.121.023578 |
Similar Items
-
Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations
by: Kongyong Cui, et al.
Published: (2021-12-01) -
Consensus Decision‐Making for the Management of Antiplatelet Therapy before Non‐Cardiac Surgery in Patients Who Underwent Percutaneous Coronary Intervention With Second‐Generation Drug‐Eluting Stents: A Cohort Study
by: Choongki Kim, et al.
Published: (2021-04-01) -
Premature Discontinuation of Dual Antiplatelet Therapy After Coronary Stenting in Veterans: Characteristics and Long‐Term Outcomes
by: Scott Kinlay, et al.
Published: (2021-05-01) -
Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients
by: Eleni M. Gamvroulas, et al.
Published: (2023-03-01) -
Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
by: Charles E. Howard, et al.
Published: (2019-10-01)